chevron_leftBack
As of 13 June 2026, PepGen Inc. has a market cap of $107.13M USD, ranking #25034 globally and #3867 in the United States.
It ranks #2238 in the Healthcare sector, and #428 in the Biotechnology industry.
Key Stats
Market Cap
$107.13MUSD
Enterprise Value
-$23.98MUSD
EBITDA (TTM)
-$92.22MUSD
Net Income (TTM)
-$89.66MUSD
PB Ratio
0.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
James McArthur
open_in_new
Employees
56
Founded
2018
IPO
06 May 2022
Website
pepgen.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.9% | -6.6% | -66% | -70% | -69% | -3.1% |
News
Loading...
PEPG Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
PEPG
PepGen Inc
ISIN: US7133171055
Shares Out.:
Shares Outstanding:
69.169M1
Shares Float:
60.708M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.55 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
170K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
149K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
26K%
|
-
|
|
NYSE: IQV
|
$26.3B
24K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
23K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
17K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
45K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
42K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
39K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
39K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
26K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
24K%
|
-
|
chevron_leftBack